Venus Remedies Ltd

Venus Remedies Q1 FY2026 Results: Revenue & Profit Surge 📈

- Consolidated Revenue: ₹131.90 Cr in Q1 FY2026 (vs ₹108.61 Cr in Q1 FY2025)

- Consolidated Net Profit: ₹9.60 Cr in Q1 FY2026 (vs ₹1.22 Cr in Q1 FY2025)

- Standalone Revenue: ₹131.85 Cr in Q1 FY2026 (vs ₹105.86 Cr in Q1 FY2025)

- Standalone Net Profit: ₹11.69 Cr in Q1 FY2026 (vs ₹4.45 Cr in Q1 FY2025)

- EPS: Consolidated ₹7.18, Standalone ₹8.75

- Subsidiary Venus Pharma GmbH has negative net worth of ₹295.40 Lakhs

- Management expects subsidiary's financial position to improve by FY2025-26 through restructuring